Prof. Marko Mihovilovic, Technical University Vienna; Dr Thomas Linder, Technical University Vienna; Prof. Verena M. Dirsch, University of Vienna; Dr David Bernhard, University of Innsbruck; Prof. Hermann Stuppner, University of Innsbruck
Within a joint research approach researchers at Vienna University of Technology, University of Innsbruck, Vienna University and Medical University of Vienna have identified novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention.
Novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention have been identified. Starting from natural compound leoligin, improved synthetic analogs were prepared with favourable properties to prevent VSMC proliferation concomitantly not affecting EC to keep blood vessel structural integrity unaffected.
The novel compounds may have highly beneficial effects for preparation of cardiac by-pass implants as well as for stent conduits. Potential applications range from administration within by-pass preparation to controlled-release devices for stents.
Collaboration, License, Purchase
AT, EP, US patents filed